Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.639
EU - Europa 7.133
AS - Asia 2.956
SA - Sud America 32
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 12
OC - Oceania 9
Totale 19.796
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.480
IE - Irlanda 1.753
SG - Singapore 1.362
IT - Italia 1.345
RU - Federazione Russa 1.125
DE - Germania 1.117
SE - Svezia 1.006
HK - Hong Kong 748
CN - Cina 468
IN - India 226
GB - Regno Unito 214
UA - Ucraina 185
CA - Canada 155
FI - Finlandia 81
NL - Olanda 51
DK - Danimarca 45
FR - Francia 45
VN - Vietnam 40
ID - Indonesia 35
AT - Austria 33
BE - Belgio 28
CZ - Repubblica Ceca 24
ES - Italia 20
TR - Turchia 19
BR - Brasile 14
IR - Iran 14
PL - Polonia 14
KR - Corea 13
EU - Europa 12
RO - Romania 10
CL - Cile 8
JP - Giappone 8
EG - Egitto 7
TW - Taiwan 7
CH - Svizzera 6
GR - Grecia 5
NO - Norvegia 5
AR - Argentina 4
AU - Australia 4
MM - Myanmar 4
PT - Portogallo 4
BG - Bulgaria 3
EE - Estonia 3
NZ - Nuova Zelanda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
CO - Colombia 2
EC - Ecuador 2
LY - Libia 2
MD - Moldavia 2
PA - Panama 2
TH - Thailandia 2
TO - Tonga 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
DZ - Algeria 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LT - Lituania 1
ME - Montenegro 1
MU - Mauritius 1
PK - Pakistan 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
Totale 19.796
Salva come PNG Salva come JPEG
Città #
Dublin 1.704
Ann Arbor 1.271
Singapore 1.153
Frankfurt am Main 938
Princeton 886
Hong Kong 739
New York 738
Fairfield 672
Ashburn 664
Chandler 662
Woodbridge 462
Houston 439
Milan 338
Lawrence 327
Altamura 321
Wilmington 300
Santa Clara 293
Cambridge 249
Seattle 239
Jacksonville 163
San Diego 160
Pune 156
Dearborn 143
Shanghai 136
Andover 89
Toronto 76
London 66
Rome 63
Nanjing 59
Washington 54
Beijing 51
Hangzhou 40
Los Angeles 40
Fremont 37
Helsinki 37
Jakarta 35
Boardman 34
Vienna 31
Guangzhou 30
Lachine 28
Chicago 25
Dallas 25
Ottawa 24
Brussels 21
Shenyang 21
Huizen 20
Tianjin 20
Cedar Knolls 18
Dong Ket 18
Kilburn 17
Bergamo 15
Esslingen am Neckar 15
Turin 15
Brno 14
Lappeenranta 14
Norwalk 14
Boston 13
Monza 13
Manchester 12
Nanchang 12
San Mateo 12
Umeå 12
Catania 11
Falls Church 11
Naples 11
Padova 11
Azzano San Paolo 10
Florence 10
Jinan 10
Mountain View 10
Groningen 9
Mumbai 9
Bonndorf 8
Hounslow 8
Modena 8
Bologna 7
Central 7
Hebei 7
Hyderabad 7
Ningbo 7
Phoenix 7
São Paulo 7
Warsaw 7
Albignasego 6
Assago 6
Brescia 6
Munich 6
Nürnberg 6
Olomouc 6
Tappahannock 6
Carate Brianza 5
Changsha 5
Indianapolis 5
Inzigkofen 5
Jiaxing 5
Montréal 5
Oslo 5
Paris 5
Pisa 5
Redmond 5
Totale 14.567
Salva come PNG Salva come JPEG
Nome #
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 287
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 231
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 191
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 190
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 182
Health Related Quality of Life in the Major Liver Conditions 180
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 180
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 178
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 176
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 173
Health related quality of life in chronic liver diseases 170
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 167
The impact of liver disease on the health-related quality of life 166
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 165
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 164
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 162
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 159
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 159
High rates of 30-day mortality in patients with cirrhosis and COVID-19 159
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 158
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 157
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 156
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 151
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 151
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 150
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 146
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 145
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 144
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 143
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 141
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 140
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 139
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 136
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 136
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 135
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 132
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 129
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 127
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 127
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 127
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 125
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 122
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 121
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 118
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 118
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 115
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 103
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 103
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness 103
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 101
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 101
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using “on demand” Approach: A Single Center Experience 99
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 99
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 96
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 91
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 91
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 90
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 90
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 89
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 87
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 85
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 83
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 76
Location and allocation: inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe 75
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 74
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 73
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 71
The societal burden of chronic liver diseases: Results from the COME study 70
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 69
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using" on demand" Approach: A Single Center Experience 69
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 66
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 66
Citolisi e colestasi post-oltx per cirrosi HCV: l’enigma della diagnosi differenziale 66
Evidence for biliary epithelial to mesenchymal transition in human cholangiocarcinoma 63
Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study 62
Aumento di alfafetoproteina in pazienti con cirrosi HBeAg+/HBVDNA+ con sieroconversione ad anti HBe, spontanea ed indotta da interferon, 62
Il nuovo immunodepressore FK 506 modula il danno acuto da D galattosamina nel ratto 62
Plasma fibronectin in acute and chronic liver diseases [FIBRONECTINA PLASMATICA NELLE EPATOPATIE ACUTE E CRONICHE. VALIDITA DELL'ANALISI QUANTITATIVA] 61
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 60
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 59
Calcio libero citoplasmatico e citotossicita' in epatociti sottoposti ad anossia 58
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 58
The use of molecular assays in the management of viral hepatitis 58
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 57
Prevalent use of Combined Prophylaxis of Hepatitis B after liver transplantation in Italy: Results of a national survey in a large cohort 57
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 57
Bergamo and Covid-19: How the Dark Can Turn to Light 57
Meet–Test–Treat for HCV management: patients’ and clinicians’ preferences in hospital and drug addiction services in Italy 57
Hormonal treatment of hepatocellular carcinoma 57
Le epatiti croniche: inquadramento nosografico 57
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 57
Correction to: Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group (Hepatology International, (2020), 14, 6, (930-943), 10.1007/s12072-020-10091-5) 57
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 56
Antibody to hepatitis C virus in hepatocellular carcinoma 56
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 55
COMBINED "EN BLOC" LIVER-PANCREAS TRANSPLANTATION USING WHOLE SIZE AND SPLIT LIVER GRAFTS 55
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 55
EVIDENCE FOR EPITHELIAL-MESENCHYMAL TRANSITION IN HUMAN CHOLANGIOCARCINOMA 54
Qualità di vita dopo trapianto di fegato per epatite fulminante 54
Razionale fisiopatologico per l'epatotossicità da Diltiazem 53
Totale 10.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.350
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.350
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.103 0 0 88 100 108 168 163 111 132 96 95 42
2020/20211.419 61 62 158 134 123 123 134 162 120 118 79 145
2021/20223.656 81 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20245.053 74 128 152 226 754 1.452 973 162 461 73 64 534
2024/20253.083 822 1.742 519 0 0 0 0 0 0 0 0 0
Totale 21.358